Details

Autor(en) / Beteiligte

• Mielgo-Rubio, Xabier
• Cardeña Gutiérrez, Ana
• Sotelo Peña, Verónica
• Sánchez Becerra, Maria Virginia
• González López, Andrea María
• Rosero, Adriana
• Trujillo-Reyes, Juan Carlos
• Couñago, Felipe

Titel

Tsunami of immunotherapy reaches mesothelioma

Ist Teil von

• World journal of clinical oncology, 2022-04, Vol.13 (4), p.267-275

Ort / Verlag

United States: Baishideng Publishing Group Inc

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor prognosis. Until very recently, patients with advanced or unresectable disease had limited treatment options, primarily based on doublet chemotherapy with cisplatin and pemetrexed. In 2020 and 2021, after more than a decade with no major advances or new drugs, two phase III clinical trials published results positioning immunotherapy as a promising option for the first- and second-line treatment of MPM. Immunotherapy has revolutionized the treatment of many cancers and is also showing encouraging results in malignant mesothelioma. Both immune checkpoint inhibition and dual cytotoxic T-lymphocyte-associated antigen 4 and programmed death-ligand 1 pathway blockade resulted in significantly improved overall survival in randomized phase III trials. In the CheckMate 743 trial, first-line therapy with nivolumab plus ipilimumab outperformed standard chemotherapy, while in the CONFIRM trial, nivolumab outperformed placebo in patients previously treated with chemotherapy. These two trials represent a major milestone in the treatment of MPM and are set to position immunotherapy as a viable alternative for treatment-naïve patients and patients with progressive disease after chemotherapy.